Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Lung cancer, one of the most deadly killers worldwide, comprises two histological subtypes: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). SCLC and NSCLC are classified as different diseases because of their distinct biology and genomic abnormalities; therefore therapeutic strategies for these two pathologies differ substantially. A recent review published by The Lancet Oncology has challenged the commonly accepted view of NSCLC and SCLC as two separated diseases highlighting the importance of improving diagnostic tools and encouraging the use of a personalized medicine approach.

Read more

Death rate in ovarian cancer has remained the same over the last 40 years because there has been little improvement in therapeutic strategies. A new study authored by a team or researchers at Cornell University and recently published in Cell offers a beacon of hope by showing that the immune system can be instructed to act as a first line of defense against ovarian cancer.

Read more

Following concerns on the cardiovascular (CV) safety of some of the last generation glucose lowering medications, Sanofi and Merck presented, during the 75th Scientific Session of the American Diabetes Association (ADA) meeting, full results of the Phase IIIb ELIXA and TECOS studies, which were designed to assess the CV safety of Lyxumia® (lixisenatide) and Januvia (sitagliptin) in adults with type 2 diabetes and high CV risk.

Read more

Metastases form when tumor cells shed from their primary site and circulate in the bloodstream before leaving the vasculature to colonize distant viable organs. These circulating tumor cells constitute seeds for subsequent growth of secondary tumors that are responsible for the vast majority of cancer related deaths.

Read more

Resistance to chemotherapy is the major factor affecting the survival rate of women who develop high-grade serous ovarian carcinoma (HGSC), the most malignant form of ovarian cancer. New findings could help anticipate which drugs are likely to be ineffective, and could buy some precious time to patients in need.

Read more